Our focus on the endocannabinoid system (ECS) is backed by an ever-expanding body of research and robust underlying science, based on the ECS as a regulator of inflammation and fibrosis in the body.1 This research demonstrates that targeting of the endocannabinoid G-protein coupled receptors, or GPCRs, CB1 and CB2, in the immune system, as well as in some key organs, reduces inflammation and inhibits or halts fibrosis with applicability across a range of potential indications and diseases.2,3,4
What is the Endocannabinoid System (ECS)?
1. González-Mariscal, Isabel et al. “Human CB1 Receptor Isoforms, present in Hepatocytes and β-cells, are Involved in Regulating Metabolism” Scientific reports, vol. 6, 33302. 19 Sep. 2016, doi:10.1038/srep33302
2. Liu, Qing-Rong, et al. “Identification of Novel Mouse and Rat CB1R Isoforms and in Silico Modeling of Human CB1R for Peripheral Cannabinoid Therapeutics.” Acta Pharmacologica Sinica, Oct. 2018, doi:10.1038/s41401-018-0152-1
3. Katchan, Valeria, et al. “Cannabinoids and Autoimmune Diseases: A Systematic Review.” Autoimmunity Reviews, vol. 15, no. 6, June 2016, pp. 513–528., doi:10.1016/j.autrev.2016.02.008
4. Rurier, Robert et al. “Cannabinoids, inflammation, and fibrosis.” The FASEB Journal, Jul. 2016